SANDRA STICKLER, BARBARA RATH, GERHARD HAMILTON^*

Oncology Research, Vol.32, No.5, pp. 799-805, 2024, DOI:10.32604/or.2024.045356

Abstract Pancreatic cancer has a dismal prognosis due to late detection and lack of efficient therapies. The Kirsten rat sarcoma virus (KRAS) oncogene is mutated in up to 90% of all pancreatic ductal adenocarcinomas (PDACs) and constitutes an attractive target for therapy. However, the most common KRAS mutations in PDAC are G12D (44%), G12V (34%) and G12R (20%) that are not amenable to treatment by KRAS G12C-directed cysteine-reactive KRAS inhibitors such as Sotorasib and Adagrasib that exhibit clinical efficacy in lung cancer. KRAS G12C mutant pancreatic cancer has been treated with Sotorasib but this mutation is detected only in 2%–3% of… More >

MENGMENG LIU^1,#, YUE PAN^1,2,#, XUFENG TAO¹, WENLI KANG¹, YINGJIE LIU¹, YONGJIE YANG^3,4,*, GARY GUISHAN XIAO^1,*

BIOCELL, Vol.46, No.10, pp. 2257-2265, 2022, DOI:10.32604/biocell.2022.020325

Abstract Pancreatic ductal adenocarcinoma (PDAC) is universally acknowledged as the cancer with the highest mortality rate. Berberine has high medicinal value and has been used as an anti-cancer agent. Hence the purpose of this study was to investigate the anti-cancer effect of berberine in PDAC. Berberine was shown to have a selective anti-cancer effect on PDAC by MTT assay in vitro. Pancreatic cancer stem cells (PCSCs), regulated by epithelial–mesenchymal transition (EMT), could promote the proliferation of PDAC cells. However, berberine suppressed the proliferation and stemness of PCSCs through immunofluorescence staining, stem cell sphere assays and so forth in vitro. In vivo,… More >